PhytoHealth Corporation announced a new clinical study results published at 2024 ESMO Congress
Combining Astragalus Polysaccharides (PG2) with standard chemoradiotherapy (CCRT) significantly improves survival rates for advanced esophageal cancer patients, according to a study by PhytoHealth Corporation. The study found that PG2, a proprietary extract of Astragalus membranaceus roots, enhances immune system modulation and tumor suppression, offering new hope for esophageal cancer treatment.
Reference News
Combining Astragalus Polysaccharides (PG2) with standard chemoradiotherapy (CCRT) significantly improves survival rates for advanced esophageal cancer patients, according to a study by PhytoHealth Corporation. The study found that PG2, a proprietary extract of Astragalus membranaceus roots, enhances immune system modulation and tumor suppression, offering new hope for esophageal cancer treatment.